AstraZeneca seeking to break 100 billion won barrier with Atacand and Crestor

Published: 2007-01-11 06:57:00

Updated: 2007-01-11 06:57:00

AstraZeneca said on January 5 its employees are rolling up its sleeves to boost sales of Atacand and Crestor up to a 100 billion-won level this year, consolidating its firmer presence in the cardiovascular sector.

The benefits of Atacand in hypertension are well documented from several trials ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK